Detalles de la búsqueda
1.
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Ann Rheum Dis
; 82(12): 1516-1526, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37699654
2.
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Ann Rheum Dis
; 82(12): 1527-1537, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37696589
3.
Changes in inpatient medicine prescribing during COVID-19 lockdown.
Intern Med J
; 53(6): 917-922, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36510392
4.
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma.
Eur Respir J
; 53(2)2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30442714
5.
Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine.
Ann Rheum Dis
; 71(10): 1630-5, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22966146
6.
Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial.
Pulm Pharmacol Ther
; 25(2): 169-77, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22306193
7.
Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial.
Pulm Pharmacol Ther
; 24(5): 563-70, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21624491
8.
Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program.
Immunotherapy
; 10(6): 473-490, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29536781
9.
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Lancet Respir Med
; 6(7): 499-510, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29793857
10.
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
J Am Soc Hypertens
; 8(11): 780-90, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25455003
11.
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Arthritis Rheumatol
; 66(12): 3255-64, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25223724
Resultados
1 -
11
de 11
1
Próxima >
>>